The fragment-based drug discovery market is estimated to be worth around USD 1.6 billion by 2030

Screening small molecule fragments has made it possible to identify pharmacological leads against otherwise hard to target hotspots on biomolecules, such as allosteric sites, rendering this approach a valuable alternative method of drug discovery

Roots Analysis is pleased to announce the publication of its recent study, titled, “Fragment-based Drug Discovery Market: Library and Service Providers, 2020-2030.”

The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of this approach over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:

A detailed review of the overall landscape of fragment-based drug discovery library and service providers.
The USD 1.6 billion (by 2030) financial opportunity within the fragment-based drug discovery market
Elaborate profiles of the companies providing libraries and services for fragment-based drug discovery (shortlisted on the basis of the service portfolio and number of fragment screening techniques offered).
An analysis of the partnerships that have been established in the recent past.
A detailed analysis on acquisition targets.
An insightful competitiveness analysis of fragment-based drug discovery library and service providers.
An analysis highlighting the cost saving potential associated with the use of fragment-based drug discovery approach.
A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

Type of Technique

X-ray Crystallography
Nuclear Magnetic Resonance
Surface Plasmon Resonance
Other Screening Techniques

Type of Service

Library Screening
Fragment Screening
Fragment Optimization

End User

Industry Players
Non-Industry Players

Key Geographical Region

North America (US and Canada)
Europe (UK, France, Germany, Spain, Italy, and rest of Europe)
Asia-Pacific (China, Japan, India, and rest of Asia-Pacific / rest of the world)

Key companies covered in the report:

2bind
Charles River Laboratories
ChemAxon
ComInnex
Creative Biolabs
Creative Biostructure
CRELUX
Domainex
Evotec
Red Glead Discovery

Press Release: Variation 1 (Format 2)

SARomics Biostructures
Shanghai ChemPartner
Sygnature Discovery
Vernalis Research

For more information, please click on the following link:

https://www.rootsanalysis.com/reports/view_document/fragment-based-drug-discovery/309.html

Other recent offerings

DNA-Encoded Libraries: Platforms and Services Market
Antibody Discovery: Services and Platforms Market (2nd Edition), 2018-2028
In Silico / Computer-Aided Drug Discovery Services Market: Focus on Large Molecules (Antibodies, Proteins, Peptides, Nucleic Acid, Gene Therapy and Vectors), 2020-2030 (Including Structure Based Drug Discovery, Fragment Based Drug Discovery, Ligand Based Drug Discovery, Target Based Drug Discovery, Interface Based Drug Discovery Approaches)

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]

About Roots Analysis

Contact Information

Roots Analysis Private Limited

Ben Johnson

+1 (415) 800 3415

[email protected]

Facebook - https://www.facebook.com/RootsAnalysis

LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/

Twitter - https://twitter.com/RootsAnalysis

Medium - https://medium.com/@RootsAnalysis

Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/